Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agent.
D000081:Acetamides / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D003520:Cyclophosphamide / Q000008:administration & dosage; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007700:Kinetics; D004915:Leukemia, Erythroblastic, Acute; D007951:Leukemia, Myeloid; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000517:prevention & control; D008770:Methylnitrosourea; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy; D051381:Rats; D014410:Tumor Stem Cell Assay
D000081:Acetamides; D008770:Methylnitrosourea; D003520:Cyclophosphamide; C014026:hexamethylene bisacetamide